# Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells

> **NCT06347068** · PHASE1 · RECRUITING · sponsor: **UNC Lineberger Comprehensive Cancer Center** · enrollment: 42 (estimated)

## Conditions studied

- Breast Cancer
- Relapse
- Resistant Cancer
- Triple Negative Breast Cancer

## Interventions

- **BIOLOGICAL:** iC9-CAR.B7-H3 T Cell Therapy
- **DRUG:** cyclophosphamide
- **DRUG:** fludarabine

## Key facts

- **NCT ID:** NCT06347068
- **Lead sponsor:** UNC Lineberger Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-27
- **Primary completion:** 2026-05
- **Final completion:** 2028-05
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2026-04-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06347068

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06347068, "Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06347068. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*